$ACUR
ACURA PHARMACEUTICALS, INC

2013 Q4 Form 10-Q Financial Statement

#000114420413058571 Filed on November 04, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q4
Revenue $35.00K $83.00K $0.00
YoY Change
Cost Of Revenue $40.00K $80.00K
YoY Change
Gross Profit $0.00 $10.00K
YoY Change
Gross Profit Margin 0.0% 12.05%
Selling, General & Admin $2.790M $1.941M $1.850M
YoY Change 50.81% 33.59% 74.53%
% of Gross Profit 19410.0%
Research & Development $800.0K $1.289M $1.210M
YoY Change -33.88% 85.2% 53.16%
% of Gross Profit 12890.0%
Depreciation & Amortization $30.00K $30.00K $30.00K
YoY Change 0.0% -25.0% 0.0%
% of Gross Profit 300.0%
Operating Expenses $3.516M $3.308M $3.057M
YoY Change 15.01% 53.93% 65.24%
Operating Profit -$3.481M -$3.225M -$3.057M
YoY Change 13.87% 50.07%
Interest Expense $60.00K $0.00 $80.00K
YoY Change -25.0% 700.0%
% of Operating Profit
Other Income/Expense, Net $35.00K -$40.00K
YoY Change 288.89%
Pretax Income -$3.420M -$3.190M -$3.020M
YoY Change 13.25% 49.07% 64.13%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.417M -$3.190M -$3.016M
YoY Change 13.3% 49.07% 82.79%
Net Earnings / Revenue -9762.86% -3843.37%
Basic Earnings Per Share -$0.07 -$0.07 -$0.06
Diluted Earnings Per Share -$0.07 -$0.07 -$0.06
COMMON SHARES
Basic Shares Outstanding 48.32M shares 47.46K shares 45.86M shares
Diluted Shares Outstanding 47.46K shares

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.07M $19.43M $27.42M
YoY Change -4.92% -33.74% -23.17%
Cash & Equivalents $12.34M $2.553M $7.476M
Short-Term Investments $13.73M $16.87M $19.95M
Other Short-Term Assets $820.0K $860.0K $270.0K
YoY Change 203.7% 138.89% -6.9%
Inventory $251.0K $300.0K $220.0K
Prepaid Expenses
Receivables $190.0K $60.00K $10.00K
Other Receivables $120.0K $120.0K $70.00K
Total Short-Term Assets $27.45M $20.77M $27.99M
YoY Change -1.92% -30.4% -22.52%
LONG-TERM ASSETS
Property, Plant & Equipment $941.0K $972.0K $1.052M
YoY Change -10.55% -9.67% 0.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $240.0K $20.00K $10.00K
YoY Change 2300.0%
Total Long-Term Assets $1.177M $996.0K $1.068M
YoY Change 10.21% -7.43% 2.3%
TOTAL ASSETS
Total Short-Term Assets $27.45M $20.77M $27.99M
Total Long-Term Assets $1.177M $996.0K $1.068M
Total Assets $28.63M $21.76M $29.06M
YoY Change -1.48% -29.6% -21.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $274.0K $253.0K $994.0K
YoY Change -72.43% 10.96% 1775.47%
Accrued Expenses $541.0K $775.0K $413.0K
YoY Change 30.99% 68.85% -13.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $1.107M $1.111M $1.424M
YoY Change -22.26% 61.72% 168.68%
LONG-TERM LIABILITIES
Long-Term Debt $9.600M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $10.00K $10.00K
YoY Change -100.0%
Total Long-Term Liabilities $9.600M $10.00K $10.00K
YoY Change 95900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.107M $1.111M $1.424M
Total Long-Term Liabilities $9.600M $10.00K $10.00K
Total Liabilities $10.71M $1.116M $1.429M
YoY Change 649.27% 61.74% 169.62%
SHAREHOLDERS EQUITY
Retained Earnings -$349.1M -$345.7M -$335.2M
YoY Change 4.15% 4.06% 2.97%
Common Stock $367.0M $366.3M $362.9M
YoY Change 1.14% 1.08% 0.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.92M $20.65M $27.63M
YoY Change
Total Liabilities & Shareholders Equity $28.63M $21.76M $29.06M
YoY Change -1.48% -29.6% -21.83%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q4
OPERATING ACTIVITIES
Net Income -$3.417M -$3.190M -$3.016M
YoY Change 13.3% 49.07% 82.79%
Depreciation, Depletion And Amortization $30.00K $30.00K $30.00K
YoY Change 0.0% -25.0% 0.0%
Cash From Operating Activities -$3.160M -$3.120M -$1.840M
YoY Change 71.74% 71.43% -2.65%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$20.00K
YoY Change -100.0% -100.0% -75.0%
Acquisitions
YoY Change
Other Investing Activities $3.180M $2.110M -$19.99M
YoY Change -115.91%
Cash From Investing Activities $3.180M $2.100M -$20.00M
YoY Change -115.9% -10600.0% 24900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.770M 2.980M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.160M -3.120M -1.840M
Cash From Investing Activities 3.180M 2.100M -20.00M
Cash From Financing Activities 9.770M 2.980M 0.000
Net Change In Cash 9.790M 1.960M -21.84M
YoY Change -144.83% -206.52% 1003.03%
FREE CASH FLOW
Cash From Operating Activities -$3.160M -$3.120M -$1.840M
Capital Expenditures $0.00 $0.00 -$20.00K
Free Cash Flow -$3.160M -$3.120M -$1.820M
YoY Change 73.63% 73.33% 0.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Inventory Write Down
InventoryWriteDown
361000 USD
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
80000 USD
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
80000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0 USD
CY2013Q3 us-gaap Inventory Write Down
InventoryWriteDown
0 USD
CY2012Q3 us-gaap Inventory Write Down
InventoryWriteDown
0 USD
us-gaap Inventory Write Down
InventoryWriteDown
0 USD
us-gaap Costs And Expenses
CostsAndExpenses
10697000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3225000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2149000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10609000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6682000 USD
CY2013Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
55000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
136000 USD
CY2012Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
9000 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1941000 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1453000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6138000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4164000 USD
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
3308000 USD
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
2149000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1289000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
696000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4120000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2518000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-3190000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2140000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10484000 USD
CY2013Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
114000 USD
CY2012Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
0 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
35000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
0 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
114000 USD
CY2012Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
35000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3076000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2140000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10484000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6652000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4790000 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6652000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
30000 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-11000 USD
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0 USD
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
35000 USD
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
125000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47458000 shares
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
30000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3190000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
945000 USD
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47522000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47297000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47520000 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47458000 shares
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47522000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47520000 shares
CY2013Q3 acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
78000 USD
CY2012Q3 acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
0 USD
acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
78000 USD
acur Cost Of Sales Excluding Inventory Write Down
CostOfSalesExcludingInventoryWriteDown
0 USD
acur Proceeds From Issuance Of Common Stock Value Under Market Offerings
ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings
102000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
71000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10516000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5200000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7611000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
70000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
51000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
13000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10708000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000 USD
acur Issuance Of Common Stock Value Under Market Offerings
IssuanceOfCommonStockValueUnderMarketOfferings
3226000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-741000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
175000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
362000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-18000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
104000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
97000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
945000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1272000 USD
acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
361000 USD
acur Provision To Reduce Inventory To Net Realizable Value
ProvisionToReduceInventoryToNetRealizableValue
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
55000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
93000 USD
us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
440000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-43000 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
4000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
536000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
129000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3073000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-129000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
716000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1046000 USD
acur Proceeds From Market Offering Of Shares
ProceedsFromMarketOfferingOfShares
-3328000 USD
acur Proceeds From Market Offering Of Shares
ProceedsFromMarketOfferingOfShares
0 USD
acur Proceeds From Issuance Of Common Stock Value Under Market Offerings
ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2520000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1036000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4923000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6365000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35685000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29320000 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
42000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
362422000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-335211000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-40000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
27630000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29054000 USD
CY2012Q3 us-gaap Royalty Revenue
RoyaltyRevenue
0 USD
us-gaap Royalty Revenue
RoyaltyRevenue
8000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
0 USD
CY2013Q3 us-gaap Revenues
Revenues
83000 USD
CY2012Q3 us-gaap Revenues
Revenues
0 USD
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
216000 USD
CY2013Q3 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
15000 USD
CY2012Q4 acur Other Accrued Taxes Current
OtherAccruedTaxesCurrent
5000 USD
CY2013Q3 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
17000 USD
CY2012Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
20000 USD
CY2013Q3 acur Manufacturing Services Costs
ManufacturingServicesCosts
0 USD
CY2012Q4 acur Manufacturing Services Costs
ManufacturingServicesCosts
21000 USD
CY2013Q3 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
76000 USD
CY2012Q4 acur Accrued Other Professional Fees Current
AccruedOtherProfessionalFeesCurrent
21000 USD
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
122000 USD
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
75000 USD
CY2013Q3 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
700000 USD
CY2012Q4 us-gaap Fifo Inventory Amount
FIFOInventoryAmount
200000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
55000 USD
CY2013Q3 acur Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
76000 USD
CY2012Q4 acur Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
0 USD
CY2013Q3 acur Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
400000 USD
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
71000 USD
acur Payment Of Royalty Maximum Contractual Term
PaymentOfRoyaltyMaximumContractualTerm
P45D
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
165000 USD
acur Royalty Payment Obligation Expiration Description
RoyaltyPaymentObligationExpirationDescription
15 years from the first commercial sale of Oxecta in such country.
acur Percentage Of Royalty Deduct To Settle Third Party Claim
PercentageOfRoyaltyDeductToSettleThirdPartyClaim
0.5 pure
acur Percentage Of Royalty Of Royalty Payable Minimum
PercentageOfRoyaltyOfRoyaltyPayableMinimum
0.8 pure
acur Patents Expiration Year
PatentsExpirationYear
2025
CY2013Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
400000 USD
CY2013Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3600000 USD
CY2013Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
449000 USD
CY2012 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
40000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1200000 USD
CY2013Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
7400000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6300000 USD
CY2013Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16900000 USD
CY2013Q3 us-gaap Inventory Net
InventoryNet
300000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
71000 USD
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
96000 USD
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19900000 USD
CY2013Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
16900000 USD
dei Trading Symbol
TradingSymbol
ACUR
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
21000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2553000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7476000 USD
CY2012Q4 us-gaap Marketable Securities
MarketableSecurities
19946000 USD
CY2012Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 USD
CY2012Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
36000 USD
CY2012Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
219000 USD
CY2012Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
43000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
271000 USD
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
27991000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1052000 USD
CY2012Q4 us-gaap Other Assets
OtherAssets
11000 USD
CY2012Q4 us-gaap Assets
Assets
29054000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
994000 USD
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
0 USD
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
20000000 USD
CY2012 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0 USD
CY2012 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
100000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
413000 USD
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
0 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12000 USD
CY2013Q3 us-gaap Other Liabilities
OtherLiabilities
5000 USD
CY2012Q4 us-gaap Other Liabilities
OtherLiabilities
5000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
1424000 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
459000 USD
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48322362 shares
dei Entity Registrant Name
EntityRegistrantName
ACURA PHARMACEUTICALS, INC
dei Entity Central Index Key
EntityCentralIndexKey
0000786947
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48322000 shares
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48322000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45867000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45867000 shares
dei Document Type
DocumentType
10-Q
us-gaap Net Income Loss
NetIncomeLoss
-6652000 USD
us-gaap Revenues
Revenues
0 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1419000 USD
us-gaap Revenues
Revenues
88000 USD
us-gaap Costs And Expenses
CostsAndExpenses
6682000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47297000 shares
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2013Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-20000 USD
CY2012Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0 USD
CY2013Q3 us-gaap Marketable Securities
MarketableSecurities
16873000 USD
CY2013Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
55000 USD
CY2013Q3 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
129000 USD
CY2013Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
298000 USD
CY2013Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0 USD
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
807000 USD
CY2013Q3 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
51000 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
20766000 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
972000 USD
CY2013Q3 us-gaap Other Assets
OtherAssets
24000 USD
CY2013Q3 us-gaap Assets
Assets
21762000 USD
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
253000 USD
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
775000 USD
CY2013Q3 us-gaap Deferred Revenue
DeferredRevenue
71000 USD
CY2013Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12000 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1111000 USD
CY2013Q3 us-gaap Liabilities
Liabilities
1116000 USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
483000 USD
CY2013Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
365863000 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345695000 USD
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
20646000 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21762000 USD
CY2013Q3 us-gaap Royalty Revenue
RoyaltyRevenue
3000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2140000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10449000 USD
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47520000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
46629000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
315000 USD
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
424000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0186 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0197 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.14 pure
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4790000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.14 pure
acur Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedForfeitures
0.0 pure
acur Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedForfeitures
0.0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.17
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5138000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47458000 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47522000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47297000 shares
CY2013Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13000000 USD
CY2013Q2 acur Proceeds From Issuance Of Common Stock Value Under Market Offerings
ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings
8000 USD
CY2013Q3 acur Sale Of Stock Number Shares Issued
SaleOfStockNumberSharesIssued
1830000 shares
CY2013Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3100000 USD
CY2013Q3 acur Proceeds From Issuance Of Common Stock Value Under Market Offerings
ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings
100000 USD
CY2013Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1900000 shares
CY2013Q3 acur Exercise Price Of Warrants
ExercisePriceOfWarrants
3.40
CY2013Q3 acur Class Of Warrant Or Right Expiration Date
ClassOfWarrantOrRightExpirationDate
August 2014
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5138000 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
45864000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
46468000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
45862000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
829000 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1658000 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
829000 shares
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1658000 shares

Files In Submission

Name View Source Status
0001144204-13-058571-index-headers.html Edgar Link pending
0001144204-13-058571-index.html Edgar Link pending
0001144204-13-058571.txt Edgar Link pending
0001144204-13-058571-xbrl.zip Edgar Link pending
acur-20130930.xml Edgar Link completed
acur-20130930.xsd Edgar Link pending
acur-20130930_cal.xml Edgar Link unprocessable
acur-20130930_def.xml Edgar Link unprocessable
acur-20130930_lab.xml Edgar Link unprocessable
acur-20130930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v357806_10q.htm Edgar Link pending
v357806_ex31-1.htm Edgar Link pending
v357806_ex31-2.htm Edgar Link pending
v357806_ex32-1.htm Edgar Link pending